Mounjaro (tirzepatide) / Eli Lilly - LARVOL DELTA

IMPACT OF GLP1 AGONIST THERAPY ON ILEAL POUCH ANAL ANASTOMOSIS PATIENT FUNCTIONAL OUTCOMES AND QUALITY OF LIFE (SSAT 2025) - "Most patients were prescribed a formulation of semaglutide (6, 42.9%) or tirzepatide (5, 35.7%)... In this case series, which is the second of its kind in the literature to the authors' knowledge, GLP1 agonist therapy was well tolerated in patients with IPAA. Although not statistically significant, a clinical reduction in use of bowel stoppers and use of other IBD agents was noticed before and after GLP1 therapy. A matched study to control patients is underway to see the impact of GLP1 compared to control patients, which will help shed light on the impact of GLP1 agonist therapy on IPAA functional outcome.Table 1."

Clinical • HEOR • Anorexia • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Summary for Patients: Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide. (PubMed, Ann Intern Med) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

ASSESSMENT OF GASTROPARESIS AND RELATED ADVERSE EVENTS ASSOCIATED WITH GLP-1 RECEPTOR AGONISTS REPORTED IN THE US FDA ADVERSE EVENT REPORTING SYSTEM (DDW 2025) - "Lowest PRR was seen in case of Exenatide PRR 0.49 (CI 0.42-0.56, P <0.001) and Zepbound PRR 0.25 (CI 0.10-0.60, P <0.0019). Impaired gastric emptying PT reports are highest in gastroparesis related AEs. Semaglutide seems to have higher association with impaired gastric emptying (PT for gastroparesis) and related AEs."

Adverse events • Gastroesophageal Reflux Disease • Gastrointestinal Disorder

CHARACTERIZATION OF REGIONAL TRANSIT DELAYS INVOLVING THE STOMACH, SMALL BOWEL, AND COLON ON GLUCAGON-LIKE PEPTIDE-1 AGONIST THERAPY: RELATION TO INDICATION FOR USE, GLYCEMIC CONTROL, AND LONG- VS. SHORT-HALF LIFE AGENTS (DDW 2025) - " Records of patients who were prescribed GLP 1 RAs before GI transit scintigraphy from 5/2021-4/2024 were searched using the terms GLP, semaglutide, tirzepatide, dulaglutide, liraglutide, and exenatide. 80/1868 patients (4.3%) were on GLP 1 RAs at the time of testing; 55/1868 (2.9%) stopped GLP 1 RAs before scintigraphy. Prevalence of delay in any region was higher on GLP 1 RAs (42/80 or 52%) vs. those who stopped them (15/55 or 25%)(P=0.002)."

Gastrointestinal Disorder

GLP-1 AGONISTS USE IS ASSOCIATED WITH LOWER USE OF PPI, ESOPHAGITIS AND ESOPHAGEAL STRICTURES IN PATIENTS WITH OBESITY AND GERD WHEN COMPARED WITH GASTRIC BYPASS: A NATIONAL DATABASE ANALYSIS (DDW 2025) - "We identified patients older than 18 with history of GERD and obesity (BMI of 30 or greater) who started GLP-1 RAs (semaglutide, liraglutide, dulaglutide and tirzepatide) between January 1, 2010, and October 31, 2024. Discussion In this retrospective study of national database, we found that patients with history of obesity and GERD who start taking GLP-1 RAs have lower odds of all-cause mortality, new use of PPI, esophageal complication and endoscopic procedures needs when compared with gastric bypass as weight loss modality. Further prospective studies are needed to determine the mechanism for these clinical findings."

Bariatric surgery • Clinical • Asthma • Barrett Esophagus • Esophageal Cancer • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Genetic Disorders • Immunology • Obesity • Oncology • Respiratory Diseases

GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USE IN PATIENTS WITH PERIANAL FISTULIZING CROHN'S DISEASE IS WELL TOLERATED AND LEADS TO WEIGHT LOSS AND CLINICAL IMPROVEMENT IN FISTULA ACTIVITY (DDW 2025) - "Of the 6 (35%) patients with active PFCD at time of GLP-1a initiation, 5 (83%) patients, who were treated with tirzepatide or semaglutide, achieved inactive PFCD within a median [IQR] of 7.8 months [5.6 to 8.3] of GLP-1a initiation. One patient had no improvement in PFCD on dulaglutide but subsequently switched to semaglutide and achieved remission of PFCD symptoms within 8 months of treatment. Conclusion : To our knowledge, this is the first study evaluating the effectiveness of GLP-1a in patients with PFCD, demonstrating both clinically significant weight loss in a majority of patients and improvement in fistula drainage and/or pain in all patients with active PFCD at the time of GLP-1a initiation with excellent GLP-1a tolerability. With limited options to treat PFCD and the rising obesity epidemic, GLP-1a therapy may hold promise as a potential therapeutic adjunct in patients with PFCD."

Clinical • Anesthesia • Crohn's disease • Diabetes • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease • Metabolic Disorders • Obesity • Pain • CRP

ASSESSMENT OF THE IMPACT OF GLP-1RA USE ON CLINICAL AND ENDOSCOPIC MEASUREMENTS IN PATIENTS WITH ULCERATIVE COLITIS WHO HAVE AN ILEAL POUCH-ANAL ANASTOMOSIS (DDW 2025) - "The GLP-1RA cohort used semaglutide, tirzepatide, liraglutide, or multiple of these agents. No association was identified between GLP-1RA use and EIPD or other clinical symptoms. Future studies should expand on these findings with the use of larger patient samples and further assessment of potential risks and benefits in this population."

Clinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Pain • Ulcerative Colitis

ASSOCIATION OF SMALL INTESTINAL BACTERIAL OVERGROWTH WITH TREATMENTS FOR MORBID OBESITY (DDW 2025) - "Four cohorts were created: GLP-1 agonist users (including agents U.S. Food and Drug Administration-approved for treatment of obesity, semaglutide, liraglutide, tirzepatide), sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), and untreated morbid obesity (UMB). There were 2,644,893 patients with morbid obesity included: 322,049 with GLP-1 agonist use; 85,614 with SG; 20,035 with RYGB; and 2,149,780 untreated. A total of 623 patients received a diagnostic code for SIBO from 10/1/2023 to 12/1/2024 (96 in GLP-1 group, 28 in SG group, 44 in RYGB group, and 455 in untreated group). Demographics and clinical variables of patients in each cohort with the diagnosis of SIBO are shown in Table 1."

Diabetes • Gastrointestinal Disorder • Genetic Disorders • Obesity • Type 2 Diabetes Mellitus

RATES OF GASTROINTESTINAL SYMPTOMS AND HEALTHCARE UTILIZATION AMONG OLDER ADULTS WITH OBESITY ON GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS (DDW 2025) - "Patients were subsequently stratified receiving a prescription for GLP-1 agonist (semaglutide, liraglutide, or tirzepatide) <12 months of diagnosis versus non-GLP-1 agonist users. In this study, 11.4% (4,977/43,690) of patients ≥ 65 years old with obesity were prescribed a GLP-1 within a year of diagnosis. Mean age for patients prescribed a GLP-1 agonist was 71 ±5 vs 74 ±7 years-old without a prescription (p<0.001). Rates of acute pancreatitis were not different among GLP-1 users vs non-users (0.7% vs 0.6%; p=0.630); however, rates of constipation (12% vs 10.6%; p<0.001), abdominal pain (14.0% vs 12.6%; p=0.001), and nausea/vomiting (10.0% vs 9.0%; p=0.001) were significantly higher among GLP-1 agonist patients."

Clinical • HEOR • Constipation • Diabetes • Gastrointestinal Disorder • Genetic Disorders • Obesity • Pain • Pancreatitis

#OZEMPTOK: A QUALITATIVE CROSS-SECTIONAL STUDY OF TRENDING SOCIAL MEDIA VIDEOS FEATURING GLP1-AGONISTS (DDW 2025) - "METHODS A thorough search was conducted on TikTok using the hashtags #glp1agonist, #wegovy, #ozempic, and #zepbound. While some videos provide valuable insights, others may spread misinformation or set unrealistic expectations, as there is no formal fact-checking mechanism. This study highlights the need for awareness and discernment when navigating the growing presence of GLP-1 agonist content on social media."

Observational data • Diabetes • Metabolic Disorders

WEIGHT LOSS OUTCOMES IN PATIENT UNDERGOING ENDOSCOPIC SLEEVE GASTROPLASTY MONOTHERAPY VERSUS GLP-1 COMBINATION THERAPY (DDW 2025) - "Patients were included if they received ESG alone or in combination with GLP-1Ras (including semaglutide, liraglutide, and tirzepatide), and excluded if they used other obesity medications or lacked 12-month follow-up data. These findings suggest patients requiring multiple therapies may represent a subset with more challenging weight loss trajectories, as they likely experienced suboptimal response to initial intervention. Further research is needed to identify optimal patient selection criteria for combination therapy versus monotherapy approaches."

Clinical • Combination therapy • Monotherapy • Genetic Disorders • Obesity

ADVERSE EVENTS OF PANCREATITIS ASSOCIATION TO VARIOUS GLP-1 RECEPTOR AGONIST: ANALYSIS PER US FDA ADVERSE REPORTING SYSTEM (DDW 2025) - "Lixisenatide has highest PRR 4.74 (CI 2.22-10.11, P <0.001). Among GLP-1 RA, there are differences in pancreatitis related AE PRR in FAERS. Higher association is found between with liraglutide and exenatide for pancreatitis, chronic pancreatitis and acute pancreatitis which is in line with earlier reports from clinical trial meta-analysis and real word AE assessments. Newer GLP-1 RA tirzepatide and dulaglutide, as per our assessment, are reported lower PRR and thus lower association signal with pancreatitis related AEs."

Adverse events • Gastrointestinal Disorder • Pancreatitis

GLP-1 RECEPTOR AGONIST USE AMONG PATIENTS SEEKING ENDOSCOPIC BARIATRIC THERAPIES: A CROSS-SECTIONAL STUDY (DDW 2025) - "The most commonly used GLP-1 was semaglutide (69.6%), followed by tirzepatide (20.1%) and liraglutide (10.3%), accounting for patients using multiple GLP-1 agonists. As GLP-1 exposure increases, EBTs will likely become an increasingly attractive solution for patients seeking long-term weight management after medication discontinuation. Future research should focus on optimizing outcomes in this growing population of GLP-exposed patients."

Clinical • Observational data • Gastrointestinal Disorder • Genetic Disorders • Obesity

ADENOMA AND SESSILE SERRATED POLYP DETECTION RATES IN ADULTS ON GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN OUTPATIENT SCREENING COLONOSCOPY (DDW 2025) - "Adult patients who used GLP-1 RA (dulaglutide, exenatide, liraglutide, semaglutide, tirzepatide) within one week of their colonoscopy were included in the treatment group, while patients who never used GLP-1 RA constituted the control group. However, adenoma detection rates were not significantly different between the two groups. Prospective studies should focus on developing specific bowel preparation protocols for GLP-1 RA users to ensure high-quality endoscopic evaluations and minimize the risks of missed lesions."

Clinical • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

IMPACT OF GLP1 AGONIST THERAPY ON ILEAL POUCH ANAL ANASTOMOSIS PATIENT FUNCTIONAL OUTCOMES AND QUALITY OF LIFE (DDW 2025) - "Most patients were prescribed a formulation of semaglutide (6, 42.9%) or tirzepatide (5, 35.7%)... In this case series, which is the second of its kind in the literature to the authors' knowledge, GLP1 agonist therapy was well tolerated in patients with IPAA. Although not statistically significant, a clinical reduction in use of bowel stoppers and use of other IBD agents was noticed before and after GLP1 therapy. A matched study to control patients is underway to see the impact of GLP1 compared to control patients, which will help shed light on the impact of GLP1 agonist therapy on IPAA functional outcome."

Clinical • HEOR • Anorexia • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

CONCOMITANT USE OF IMMUNE CHECKPOINT INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS DO NOT INCREASE THE RISK FOR ACUTE PANCREATITIS: A POPULATION-BASED COHORT STUDY IN THE UNITED STATES (DDW 2025) - "We included patients who received GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide and tirzepatide) and ICIs drugs (ipilimumab, nivolumab, pembrolizumab, atezolizumab, atezolizumab, avelumab, durvalumab, relatlimab and cemiplimab) between January 1, 2010, and October 31, 2024. In fact, patients who are taking both medications have lower odds of sepsis, AKI, need for mechanical ventilation, and need for TPN in patients who develop AP. Further prospective studies are needed to determine the mechanisms behind these findings."

Checkpoint inhibition • Clinical • Acute Kidney Injury • Dyslipidemia • Gastrointestinal Disorder • Hypertriglyceridemia • Infectious Disease • Nephrology • Oncology • Pancreatic Cancer • Pancreatitis • Renal Disease • Septic Shock

GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS DO NOT INCREASE THE RISK FOR RECURRENT ACUTE PANCREATITIS AND ARE NOT ASSOCIATED WITH LOCAL COMPLICATIONS IN PATIENTS WHO DEVELOP IT: A POPULATION-BASED COHORT STUDY IN THE UNITED STATES (DDW 2025) - "GLP-1 RA cohort (semaglutide, liraglutide, dulaglutide and tirzepatide) from this set were matched to non GLP-1 RA cohort based on age, demographics, comorbidities, and medication by using 1:1 propensity matching. GLP-1 RA cohort had a lower all-cause mortality, lower risk of sepsis, lower need for mechanical ventilation in patients who developed RAP. Further prospective studies are needed to determine the mechanisms behind these findings."

Clinical • Acute Kidney Injury • Dyslipidemia • Hypertriglyceridemia • Infectious Disease • Nephrology • Pancreatitis • Renal Disease • Septic Shock

DIFFERENTIAL EFFECTS OF GLP-1 AGONISTS ON CHROMATIN MODULATION (DDW 2025) - "These findings suggest that semaglutide and tirzepatide exert certain effects on chromatin architecture and transcriptional plasticity in colorectal cell lines, with implications for their role in early carcinogenesis and cancer therapy. Future research should explore the molecular pathways underpinning these observations to better understand the therapeutic potential of GLP-1 agonists in cancer biology."

Oncology • DKK3 • E2F2 • SPON2 • TXNIP

UNDERSTANDING PATIENT ADHERENCE TO GLUCAGON-LIKE-PEPTIDE-1 AGONISTS FOR WEIGHT LOSS: A SURVEY STUDY (DDW 2025) - "Of those, 72% of patients were taking or previously took Semaglutide, while 18% of patient were taking or previously took Tirzepatide... GLP-1 RAs are proven highly efficacious for sustained weight loss if adherence is maintained. However, our survey demonstrated significant knowledge gaps regarding appropriate medication administration, and lack of long-term adherence. These factors coupled with the high rates of side effects of GLP-1-RAs, can limit its effectiveness as a sustainable weight loss solution."

Adherence • Clinical • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Obesity

RISK OF SUICIDE AND SELF HARM BEHAVIOR IN PATIENTS ON GLP-1 RECEPTOR AGONISTS: SYSTEMATIC REVIEW OF DISPROPORTIONALITY ANALYSIS AND A META-ANALYSIS OF PUBLISHED STUDIES (DDW 2025) - "Review of all DPAs showed only positive associations as semaglutide-associated SSHB (ROR, 1.45; 95% CI, 1.18-1.77; IC, 0.53; 95% CI, 0.19-0.78) in one study, Semaglutide [ROR = 0.60 (0.51–0.71)] and liraglutide [ROR = 0.28 (0.23–0.35)] had higher suicidal events than comparable agents in another; positive with liraglutide (ROR=1.64), semaglutide (ROR =2.03), tirzepatide (ROR =1.76) but significantly less than comparable agents in third study, mixed results in fourth and no signals in fifth study. This meta-analysis shows that patients on GLP1-RAs had higher SSHB's, but lower mortality rates compared to controls. This association is concerning and should encourage further research. Various environmental, physiologic, and co-medication with other agents like psychotropics may be possible associated factors."

Retrospective data • Review • Genetic Disorders • Obesity • Psychiatry • Suicidal Ideation • ROR1

GLP-1 AGONISTS USE IS ASSOCIATED WITH LOWER ALL-CAUSE HOSPITALIZATION AND DIVERTICULITIS IN PATIENTS WITH DIVERTICULAR DISEASE AND OBESITY WHEN COMPARED WITH GASTRIC BYPASS: A NATIONAL DATABASE ANALYSIS (DDW 2025) - "We identified patients older than 18 with history of DD and obesity (BMI of 30 or greater) who started GLP-1 RAs (semaglutide, liraglutide, dulaglutide and tirzepatide) between January 1, 2010, and October 31, 2024. Discussion In this retrospective study of a national database, patients with a history of DD and obesity who are taking GLP-1 RAs have lower odds of all-cause mortality, AHA, UD, partial colectomy, colonoscopy as well as systemic complications when compared with those having gastric bypass as a weight loss therapy. Further prospective studies are needed to determine the mechanism for these clinical findings."

Bariatric surgery • Clinical • Acute Kidney Injury • Gastrointestinal Disorder • Genetic Disorders • Infectious Disease • Nephrology • Obesity • Renal Disease • Septic Shock

TRENDS IN GLUCAGON-LIKE PEPTIDE-1 AGONIST (GLP-1A) PRESCRIBING FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE (DDW 2025) - "Semaglutide (53%) and tirzepatide (29%) were the most commonly prescribed GLP-1a medications ( Table 1 )... To date, this is the largest study of GLP-1a use for obesity in patients with IBD. GLP-1a prescriptions in IBD patients are increasing, paralleling trends seen in the general population. While endocrinologists and internists are the primary prescribers of GLP-1a for patients with IBD, gastroenterologists need to be knowledgeable about the eligibility, safety and efficacy of these agents in order to offer timely obesity interventions, reducing cardiometabolic disease and improving overall outcomes."

Clinical • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Obesity

DOES WITHHOLDING GLP-1 RECEPTOR AGONISTS REDUCE ASPIRATION RISK IN ENDOSCOPY? A NATIONWIDE COHORT STUDY (DDW 2025) - "Among GLP-1RA users, 64% were on semaglutide, 37% on dulaglutide, 20% on liraglutide, and 12% on tirzepatide. These findings suggest that withholding GLP-1RA, as recommended by some guidance statements, may not be necessary to reduce aspiration risk. In the abscence of randomized controlled trials providing definitive evidence, an individualized approach to managing GLP-1RA in the preoperative setting—considering its indications alongside other risk factors such as age and GI symptoms—may be appropriate."

Anesthesia • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Obesity • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

COMPARATIVE REAL-WORLD ANALYSIS OF WEIGHT LOSS OUTCOMES AND SIDE EFFECT PROFILES BETWEEN SEMAGLUTIDE AND TIRZEPATIDE: A MULTICENTERED STUDY (DDW 2025) - "In our study, we demonstrate better weight loss outcomes with tirzepatide compared to semaglutide in a real-world setting, despite a higher prevalence of diabetes and fewer dietitian visits. Further studies are needed to confirm these results and to better understand the long-term effectiveness and safety of these medications."

Adverse events • Clinical • Real-world • Real-world evidence • Diabetes • Genetic Disorders • Obesity

TIRZEPATIDE SHOWS LOWER RISK OF GASTROINTESTINAL SIDE EFFECTS COMPARED TO OTHER GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS: A REAL-WORLD ANALYSIS OF OVER 1 MILLION PATIENTS (DDW 2025) - "Conclusion Our study provides real-world evidence that Tirzepatide has a significantly lower risk of GI side effects compared to GLP-1 RAs, suggesting a favorable GI safety profile for patients with obesity or type 2 diabetes. However, long-term studies are needed to confirm these findings."

Adverse events • Clinical • Real-world • Real-world evidence • Barrett Esophagus • Cardiovascular • Congestive Heart Failure • Constipation • Diabetes • Dyspepsia • Fibrosis • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Genetic Disorders • Heart Failure • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders • Obesity • Oncology • Pancreatic Cancer • Pancreatitis • Type 2 Diabetes Mellitus